Stock Ratings / Health Care / SLS / dividends

SRPT (35) GENB (61) ZYME (47) SEPN (62) ⌘ Pro Terminal →

SELLAS Life Sciences Group Inc. (SLS) Dividend Safety Gauge & 10-Year DRIP Compounder

$10.15 -2.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

SELLAS Life Sciences Group Inc. (SLS) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $2.05B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLS)Realized 20D OHLCV Swing Band: ±12.5%

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLS)

✓Walkthrough of SLS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +105.05%🛡️ HOLDING TREND SUPPORT

2026-10-30O $9.63H $10.15L $9.30C $10.15VOL 6.15M

RES: $15.39SUP: $9.85SMA50: $12.16SMA200: $8.57

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLS Butterfly Map → + Track SLS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SLS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLS)

Health Care Rank #812 of 1016 ⚔️ SRPT vs SLS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLS vs. SRPT, GENB, ZYME, SEPN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SELLAS Life Sciences Group Inc. (SLS) ranks #812 by composite RQD confidence (35/100, grade D-) and #257 by equity capitalization ($2.05B). Within this direct 5-issuer industry benchmark cohort, SLS leads on earnings valuation at N/A trailing P/E, while SEPN leads on capital efficiency and profitability with -20.7% ROIC and — gross margin. SEPN currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with SLS at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SLS ACTIVE SELLAS Life Sciences Group Inc.	D-	35/100	—	—	-21.8%	-2.17%	$2.05B	Benchmark Subject
SRPT Sarepta Therapeutics Inc.	D-	35/100	—	96.0%	-35.0%	-0.47%	$2.03B	/srpt-vs-sls →
GENB Generate Biomedicines Inc.	C-	61/100	—	—	—	+2.54%	$2.02B	/genb-vs-sls →
ZYME Zymeworks Inc.	D	47/100	—	—	-32.2%	-0.66%	$2.02B	/zyme-vs-sls →
SEPN Septerna Inc.	C	62/100	—	—	-20.7%	+2.22%	$2.11B	/sepn-vs-sls →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001390478

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SELLAS Life Sciences Group Inc. (SLS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$26.9M, operating cash flow of -$28.4M, and free cash flow of -$28.4M (+19.8% YoY). On the balance sheet, SLS closed FY2025 with $78.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$26.9M	-$28.4M	-$28.4M	$78.3M	—
FY2024 (FY)	2024-12-31	$0	-$30.9M	-$35.4M	-$35.4M	$19.4M	—
FY2023 (FY)	2023-12-31	$0	-$37.3M	-$31.4M	-$31.4M	—	—

3. SLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, SELLAS Life Sciences Group Inc. (NASDAQ: SLS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $10.15 (-2.17% 1D, market cap $2.05B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SLS ranks #812 in composite RQD confidence.

How does SLS compare to SRPT and GENB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SLS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -21.8%. By comparison, SRPT (Sarepta Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B) and GENB (Generate Biomedicines Inc.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.02B). Among the 5-stock peer group, SLS leads on earnings multiple (N/A) while SEPN leads on capital efficiency (-20.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SLS?

Per SLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001390478), SELLAS Life Sciences Group Inc. generated $0 in revenue, -$26.9M in net income, and -$28.4M in free cash flow against $78.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SLS trading relative to its 50-day, 200-day, and 52-week technical levels?

SLS last traded at $10.15 (-2.17% on volume of 8,357,909 shares), positioning the stock -16.53% below its 50-day simple moving average ($12.16) and +18.44% above its 200-day simple moving average ($8.57). Across its 52-week range of $1.39 to $15.88, SLS sits at the 60.5% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.88 to $11.42).

SLS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SLS pay a dividend and is it safe?

SELLAS Life Sciences Group Inc. (SLS) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SLS RQD Cockpit SLS 12M Forecast SLS Earnings & Move SLS Dividends & DRIP SLS Insiders & 13F SLS Whale Options SLS Profit Sankey SLS News & Why